Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Humacyte, Inc.
Report date August 17, 2023 · Filed August 21, 2023
Section 16 reporting ended · disclosed 2023-08-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,191,140 |
Ending reported balance
After 2023-08-21 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-08-17 · Sale · Disposed 570,174 · Balance 9,420,562 F1: Between August 17, 2023 and August 21, 2023, the Reporting Person sold 1,799,596 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. F2: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $4.13. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2023-08-18 · Sale · Disposed 626,979 · Balance 8,793,583 F1: Between August 17, 2023 and August 21, 2023, the Reporting Person sold 1,799,596 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. F3: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $3.75. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2023-08-21 · Sale · Disposed 602,443 · Balance 8,191,140 F1: Between August 17, 2023 and August 21, 2023, the Reporting Person sold 1,799,596 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. F4: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.22 to $3.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Between August 17, 2023 and August 21, 2023, the Reporting Person sold 1,799,596 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.
F2: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $4.13. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $3.75. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.22 to $3.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2023 Filed Aug 21, 2023 18:07 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 602,443 | $3.39 | $2,042,281.77 |
DisclosureSEC source: 0001818382-23-000119 · wf-form4_169265561875582.xml · nonDerivative · entry 3 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,191,140 F1 · shares: Between August 17, 2023 and August 21, 2023, the Reporting Person sold 1,799,596 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.22 to $3.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 18:07 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 626,979 | $3.57 | $2,238,315.03 |
DisclosureSEC source: 0001818382-23-000119 · wf-form4_169265561875582.xml · nonDerivative · entry 2 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,793,583 F1 · shares: Between August 17, 2023 and August 21, 2023, the Reporting Person sold 1,799,596 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $3.75. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 18:07 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 570,174 | $3.68 | $2,098,240.32 |
DisclosureSEC source: 0001818382-23-000119 · wf-form4_169265561875582.xml · nonDerivative · entry 1 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,420,562 F1 · shares: Between August 17, 2023 and August 21, 2023, the Reporting Person sold 1,799,596 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $4.13. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:04 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 500,000 | $3.12 | $1,558,750.00 |
DisclosureSEC source: 0001818382-23-000081 · wf-form4_168694584708349.xml · nonDerivative · entry 1 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,990,736 F1 · shares: On June 15, 2023, the Reporting Person sold 500,000 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 16:17 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 4,875,000 | $2.60 | $12,675,000.00 |
DisclosureSEC source: 0001818382-23-000047 · wf-form4_168686024922892.xml · nonDerivative · entry 1 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,490,736 F1 · shares: On June 13, 2023, the Reporting Person sold 4,875,000 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Read SEC document |
| May 25, 2023 Filed May 26, 2023 17:02 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 2,625,000 | $2.75 | $7,218,750.00 |
DisclosureSEC source: 0001104659-23-065543 · tm2317123-7_4seq1.xml · nonDerivative · entry 1 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,365,736 F1 · shares: On May 25, 2023, the Reporting Person sold 2,625,000 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 20:19 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 239,538 | $2.53 | $606,031.14 |
DisclosureSEC source: 0001818382-22-000219 · wf-form4_167149916039845.xml · nonDerivative · entry 1 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,990,736 F1 · shares: On December 16, 2022, the Reporting Person sold 239,538 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.50 to $2.63. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2022 Filed Dec 15, 2022 19:46 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 93,426 | $2.63 | $245,710.38 |
DisclosureSEC source: 0001818382-22-000209 · wf-form4_167115157790775.xml · nonDerivative · entry 3 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,230,274 F1 · shares: On December 13, 14 and 15, 2022, the Reporting Person sold 330,000, 276,304 and 93,426 shares of Common Stock, respectively. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.60 to $2.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 19:46 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 276,304 | $2.76 | $762,599.04 |
DisclosureSEC source: 0001818382-22-000209 · wf-form4_167115157790775.xml · nonDerivative · entry 2 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,323,700 F1 · shares: On December 13, 14 and 15, 2022, the Reporting Person sold 330,000, 276,304 and 93,426 shares of Common Stock, respectively. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.75 to $2.87. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 19:46 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 330,000 | $2.84 | $937,200.00 |
DisclosureSEC source: 0001818382-22-000209 · wf-form4_167115157790775.xml · nonDerivative · entry 1 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600,004 F1 · shares: On December 13, 14 and 15, 2022, the Reporting Person sold 330,000, 276,304 and 93,426 shares of Common Stock, respectively. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.77 to $3.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 16:33 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 1,522,500 | $4.00 | $6,090,000.00 |
DisclosureSEC source: 0001818382-22-000159 · wf-form4_166361956732744.xml · nonDerivative · entry 1 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,930,004 F1 · shares: The sale was made by the Reporting Person in a block trade. The purchaser is an existing investor of the Issuer, who had previously participated in the Issuer's PIPE financing transaction, and was interested in increasing its ownership of the Humacyte, Inc. The transaction enabled Mr. Brady Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for the purchaser to acquire a large block of shares at a time that Humacyte, Inc. was not conducting a financing and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:13 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 1,522,500 | $10.00 | $15,225,000.00 |
DisclosureSEC source: 0001104659-21-110538 · tm2125954-22_4seq1.xml · nonDerivative · entry 2 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,452,504 Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:13 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantCommon Stock | 18,930,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110538 · tm2125954-22_4seq1.xml · nonDerivative · entry 1 Ayabudge LLC · CIK 0001878024 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,930,004 F1 · price: On August 26, 2021, Alpha Health care Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.